肺高血压在间歇性肺病中的演变:穿越过去,现在和未来的旅程
Ahmad Arslan1, Jorden Smith1, Muhammad Raheel Qureshi1
1Division of Pulmonary, Critical Care and Sleep Medicine, University of South Florida, Tampa, FL, United States.
间歇性肺部疾病 (ILD) 中的肺高血压 (PH) 恶化了结果. 早期查和吸入Treprostinil为管理这种具有挑战性的疾病提供了新的希望.
科学领域:
- 肺部医学 肺部医学
- 心脏病学 心脏病学
- 呼吸系统疾病 呼吸系统疾病
背景情况:
- 间歇性肺部疾病 (ILD) 经常发展为肺高血压 (PH),特别是世卫组织第三组PH.
- 在ILD中PH显著增加死亡率和发病率,呈现出比其他PH组更糟糕的预后.
- 由于症状重叠,在ILD中早期检测PH具有挑战性,但对于改善患者的治疗结果至关重要.
研究的目的:
- 审查目前对ILD中毛囊前PH的理解.
- 讨论在ILD中PH的诊断和管理策略.
- 突出最近在治疗与ILD相关的PH方面的进展和未来方向.
主要方法:
- 审查现有的文献关于在ILD的PH.
- 对临床试验数据的分析,包括INCREASE研究.
- 讨论当前和新兴的治疗方法.
主要成果:
- 世卫组织3组PH在ILD带来了一个糟糕的预后.
- 在INCREASE研究中证明的吸入式特雷普罗斯提尼尔是FDA批准的第一个用于ILDPH的治疗方法.
- 尽管取得了进展,但在ILD中PH的整体前景仍然严峻.
结论:
- 由于新的治疗选择,在ILD中临床治疗PH的临床方法中发生了范式转变.
- 对于在ILD患者中早期检测PH的验证查工具有极大需求.
- 对新药开发的持续研究对于改善长期管理和患者结果至关重要.
更多相关视频
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
